Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A clinical study for treatment of psoriasis with CYPS317

Next Previous
Trial Profile

A clinical study for treatment of psoriasis with CYPS317

Status: Planning
Phase of Trial: Phase I/II

Latest Information Update: 06 Mar 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs CYPS-317 (Primary)
  • Indications Psoriasis
  • Focus Adverse reactions; First in man

Most Recent Events

  • 24 Feb 2026 According to a FibroBiologics media release, company received IND clearance for the treatment of psoriasis with CYPS317, in the first half of 2026.
  • 31 Dec 2025 According to a FibroBiologics media release, the company announced the filing of a Phase 1/2 Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) seeking regulatory clearance to initiate clinical trials of CYPS317 for the treatment of moderate to severe psoriasis.
  • 31 Oct 2025 According to a FibroBiologics media release, company is planning to complete the trial in third quarter of 2026.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top